Načítá se...
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Immune checkpoint blockade (ICB) immunotherapy induces potent antitumor immunity across multiple solid tumors, although few patients respond well to this therapy. An emerging biomarker for predicting responsiveness to ICB immunotherapy is tumor mutational burden (TMB). Although several surrogate bio...
Uloženo v:
| Vydáno v: | JCI Insight |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6542599/ https://ncbi.nlm.nih.gov/pubmed/31092729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.127901 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|